Rescue Medication Use Before, During, and After an Exacerbation of Chronic Obstructive Pulmonary Disease: Post-hoc Analysis of the ETHOS Study (ID 414)
UCL Respiratory, University College London, London, UK
Previously submitted to and presented at the American Thoracic Society 2022, 13−18 May.
Published abstract citation: Hurst J, Ferguson GT, Rabe KF, Darken P, Patel M, Dorinsky P. Rescue Medication Use Before, During, and After COPD Exacerbations: Post-Hoc Analysis of the ETHOS Study. American Thoracic Society - 118th International Conference. 2022;205:A1452. URL: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A1452
Funding: This study was supported by AstraZeneca.
Conflicts of interest: John R Hurst is a consultant for AstraZeneca, is an advisory committee member for AstraZeneca, Boehringer Ingelheim, Chiesi, and Novartis, and is a speaker for AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, and Takeda.
Gary T Ferguson is a consultant for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva, Theravance, and Verona, is an advisory committee member for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Theravance, and Verona, is a speaker for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Teva, and Theravance, and receives research grants from Amphastar, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Teva, Theravance, and Verona; and has previously been a consultant and advisory board member for, and received research grants from, Sunovion.
Klaus F Rabe is a consultant, advisory committee member, and speaker for AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Orion Menarini, and Sanofi Regeneron.
Patrick Darken and Mehul Patel are employees of AstraZeneca and hold stock and/or stock options in the company.
Paul Dorinsky is a former employee of AstraZeneca and previously held stock and/or stock options in the company.
The conference has been instigated and organised by PCRS. We are grateful to sponsors and exhibitors who have contributed funding towards this event in return for exhibition space. Neither sponsors or exhibitors have had any input into the agenda or the selection of speakers with the exception of any sponsored satellite symposia which are clearly indicated. View the full list of sponsors.
The conference social programme - dinner, drinks and disco - is not covered by sponsorship or exhibition fees.